The National Library of Medicine (NLM) is pleased to announce four upcoming enhancements to PubMed.

1. Conflict of Interest Statements (COIS)

PubMed will include conflict of interest statements below the abstract when these statements are supplied by the publisher (see Figure 1).

**Culture and Process Change as a Priority for Patient Engagement in Medicines Development.**

Boutin M¹, Dewulf L², Hoos A¹, Geissler C¹, Tedaro V¹, Schneider RF¹, Garzya V¹, Garvey A¹, Robinson P², Saffer T¹, Kug S¹, Sargeant L¹².

**Abstract**

Patient Focused Medicines Development (PFMD) is a not-for-profit independent multinational coalition of patients, patient stakeholders, and the pharmaceutical industry with interests across diverse disease areas and conditions. PFMD aims to facilitate an integrated approach to medicines development with all stakeholders involved early in the development process. A key strength of the coalition that differentiates it from other groups that involve patients or patient groups is that PFMD has patient organizations as founding members, ensuring that the patient perspective is the starting point when identifying priorities and developing solutions to meet patients’ needs. In addition, PFMD has from inception been formed as an equal collaboration among patient groups, patients, and pharmaceutical industry and has adopted a unitrans-Atlantic setup and scope that reflects its global intent. This parity extends to its governance model, which ensures at least equal or greater share of voice for patient group members. PFMD is actively inviting additional members and aims to expand the collaboration to include stakeholders from other sectors. The establishment of PFMD is particularly timely as patient engagement (PE) has become a priority for many health stakeholders and has led to a surge of mostly disconnected activities to deliver this. Given the current plethora of PE initiatives, an essential first step has been to determine, based on a comprehensive mapping, those strategic areas of most need requiring focused initial effort from the perspective of all stakeholders. PFMD has identified four priority areas that will need to be addressed to facilitate implementation of PE. These are (1) culture and process change, (2) development of a global meta-framework for PE, (3) information exchange, and (4) training. This article discusses these priority themes and ongoing or planned PFMD activities within each.

**KEYWORDS:** patient engagement priorities medicines development

PMID: 28232676 PMCID: PMC5332122 DOI: 10.1177/2160473016659104

Conflict of interest statement: The following authors are employees: LD (UCB Biopharma); AH (Amgen [Europe] GmbH); RS (Pfizer Inc); (AstraZeneca); AG (GlaxoSmithKline); PR (Merck Sharp & Dohme Ltd); IS (Ismedica Ltd: medical writing and editorial support).
2. Editorial Expressions of Concern

NLM is adding editorial expressions of concern as a new pair of linking elements in the Comments/Corrections suite in PubMed. Expressions of concern, previously handled as comments, will be labeled explicitly in the abstract display (see Figure 2).

Figure 2. Labels for the new Expression of Concern linking elements.

3. Results Display

The "Per page" menu, which allows users to customize the number of items that appear on the results screen, will appear at the top of the results list (see Figure 3).

Figure 3. "Per page" menu at the top of the results display.
4. Status Tag

The status tag [PubMed – indexed for MEDLINE] will be replaced with the tag [Indexed for MEDLINE] (see Figure 4).

Figure 4. New [Indexed for MEDLINE] status tag in abstract view.

The Abstract display in PubMed will include a status tag only if the citation is indexed for MEDLINE. Additional status tags will still appear in the MEDLINE and XML displays. The citation status search strategies will continue to function as they always have. Please see Citation Status Subsets in online help for more information.

By Marie Collins
National Center for Biotechnology Information